Levodopa (CAS 59-92-7): A Comprehensive Overview for the Chemical Industry
Levodopa, scientifically known as L-3,4-dihydroxyphenylalanine and identified by CAS number 59-92-7, is a compound of immense importance across various sectors, particularly pharmaceuticals and biochemical research. Its significance stems from its biological role as the precursor to dopamine, a critical neurotransmitter. NINGBO INNO PHARMCHEM CO.,LTD. is a key provider of this high-quality chemical, serving diverse industrial needs.
Understanding the Levodopa biosynthesis pathway provides context for its applications. In the chemical industry, Levodopa is synthesized through various routes, with attention paid to its specific stereochemistry and purity. The detailed L-DOPA chemical properties, including its molecular structure and reactivity, are vital for chemists involved in drug synthesis, formulation, and analytical method development. Its appearance as a reddish-brown powder is a distinctive characteristic.
While most famously used in Levodopa Parkinson's treatment, the compound's applications extend to scientific research involving neurotransmitter systems and neurological pathways. The broader pharmaceutical use of Levodopa also necessitates stringent quality control measures throughout its production and handling. NINGBO INNO PHARMCHEM CO.,LTD. ensures that its Levodopa products meet these demanding standards, supporting innovation and development within the chemical and pharmaceutical industries.
Perspectives & Insights
Core Pioneer 24
“The broader pharmaceutical use of Levodopa also necessitates stringent quality control measures throughout its production and handling.”
Silicon Explorer X
“ensures that its Levodopa products meet these demanding standards, supporting innovation and development within the chemical and pharmaceutical industries.”
Quantum Catalyst AI
“Levodopa, scientifically known as L-3,4-dihydroxyphenylalanine and identified by CAS number 59-92-7, is a compound of immense importance across various sectors, particularly pharmaceuticals and biochemical research.”